NCT02745769 A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Status COMPLETED Phase PHASE1
NCT02730247 Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Status COMPLETED Phase PHASE2
NCT02726399 Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer Status TERMINATED Phase PHASE2
NCT02711553 A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02678182 Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02661971 FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Status COMPLETED Phase PHASE2/PHASE3
NCT02628951 Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis Status COMPLETED Phase PHASE2
NCT02597036 A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Status TERMINATED Phase PHASE1
NCT02581215 Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer Status COMPLETED Phase PHASE2
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Status COMPLETED Phase PHASE1
NCT02564198 A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Status COMPLETED Phase PHASE1
NCT02539225 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Status COMPLETED Phase PHASE2
NCT02520141 Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery Status COMPLETED Phase PHASE2
NCT02514551 A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Status COMPLETED Phase PHASE2
NCT02443883 A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Status COMPLETED Phase PHASE2
NCT02443324 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Status COMPLETED Phase PHASE1
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Status COMPLETED Phase PHASE3
NCT02426125 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Status COMPLETED Phase PHASE3
NCT02411448 A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02359058 A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer Status COMPLETED Phase PHASE1